Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We are analyzing https://www.nature.com/articles/s41541-020-0159-8.

Title:
The promise of mRNA vaccines: a biotech and industrial perspective | npj Vaccines
Description:
mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {πŸ“š}

  • Education
  • Science
  • Politics

Content Management System {πŸ“}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {πŸ’Έ}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {πŸ’°}


Display Ads {🎯}

$63,100 per month
Our analysis indicates Nature.com generates between $42,042 and $115,616 monthly online from display ads.

Keywords {πŸ”}

mrna, pubmed, article, google, scholar, cas, vaccines, vaccine, central, rna, delivery, clinical, nature, cap, constructs, development, cell, immune, data, translation, protein, translational, human, mol, infectious, diseases, manufacturing, efficiency, candidate, expression, lipid, optimization, studies, safety, content, sam, system, nucleic, ther, mrnabased, addition, systems, nrm, polymerase, construct, responses, vitro, properties, immunogenicity, formulations,

Topics {βœ’οΈ}

/news-releases/news-release-details/moderna-announces-funding-award-barda-8-million-potential-125 /news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data nature portfolio /news/curevac-announces-positive-results privacy policy professional antigen-presenting cells gov/archives/edgar/data/1682852/000119312519243385/d796420dex993 favorable therapeutic index cellular library screening advertising research nature nature 543 social media open-reading frame moderna reported pipeline reprints early-phase clinical studies early-phase human studies positive-stranded mrna viruses early-phase clinical trials dna-dependent rna polymerase anti-reverse cap analogs open-label high-pressure liquid chromatography multi-antigen candidates necessitate limit multi-antigen approaches mrna-based vaccines hold cellular ifn-induced proteins lipid-encapsulated mrna encoding multi-antigen vaccine approaches mrna rabies vaccine mrna-based chikungunya vaccine author correspondence original author permissions central advantages hinges limited data exist 2β€²o-unmethylated capped rna control infectious diseases specific details amino lipid series unwanted inflammatory impurities translational medicine tools published maps adaptive immune responses acceptable risk/benefit profile decision-making process multi-antigen approaches significantly higher levels

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:The promise of mRNA vaccines: a biotech and industrial perspective
         description:mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries.
         datePublished:2020-02-04T00:00:00Z
         dateModified:2020-02-04T00:00:00Z
         pageStart:1
         pageEnd:6
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1038/s41541-020-0159-8
         keywords:
            Infectious diseases
            Vaccines
            Biomedicine
            general
            Medical Microbiology
            Virology
            Public Health
            Vaccine
            Infectious Diseases
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41541-020-0159-8/MediaObjects/41541_2020_159_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41541-020-0159-8/MediaObjects/41541_2020_159_Fig2_HTML.png
         isPartOf:
            name:npj Vaccines
            issn:
               2059-0105
            volumeNumber:5
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Nicholas A. C. Jackson
               affiliation:
                     name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building
                     address:
                        name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kent E. Kester
               url:http://orcid.org/0000-0002-5056-0802
               affiliation:
                     name:Sanofi Pasteur
                     address:
                        name:Sanofi Pasteur, Swiftwater, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Danilo Casimiro
               affiliation:
                     name:Sanofi Pasteur
                     address:
                        name:Sanofi Pasteur, Swiftwater, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sanjay Gurunathan
               affiliation:
                     name:Sanofi Pasteur
                     address:
                        name:Sanofi Pasteur, Swiftwater, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Frank DeRosa
               affiliation:
                     name:Translate Bio
                     address:
                        name:Translate Bio, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The promise of mRNA vaccines: a biotech and industrial perspective
      description:mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries.
      datePublished:2020-02-04T00:00:00Z
      dateModified:2020-02-04T00:00:00Z
      pageStart:1
      pageEnd:6
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1038/s41541-020-0159-8
      keywords:
         Infectious diseases
         Vaccines
         Biomedicine
         general
         Medical Microbiology
         Virology
         Public Health
         Vaccine
         Infectious Diseases
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41541-020-0159-8/MediaObjects/41541_2020_159_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41541-020-0159-8/MediaObjects/41541_2020_159_Fig2_HTML.png
      isPartOf:
         name:npj Vaccines
         issn:
            2059-0105
         volumeNumber:5
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Nicholas A. C. Jackson
            affiliation:
                  name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building
                  address:
                     name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kent E. Kester
            url:http://orcid.org/0000-0002-5056-0802
            affiliation:
                  name:Sanofi Pasteur
                  address:
                     name:Sanofi Pasteur, Swiftwater, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Danilo Casimiro
            affiliation:
                  name:Sanofi Pasteur
                  address:
                     name:Sanofi Pasteur, Swiftwater, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sanjay Gurunathan
            affiliation:
                  name:Sanofi Pasteur
                  address:
                     name:Sanofi Pasteur, Swiftwater, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Frank DeRosa
            affiliation:
                  name:Translate Bio
                  address:
                     name:Translate Bio, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:npj Vaccines
      issn:
         2059-0105
      volumeNumber:5
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building
      address:
         name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building, London, UK
         type:PostalAddress
      name:Sanofi Pasteur
      address:
         name:Sanofi Pasteur, Swiftwater, USA
         type:PostalAddress
      name:Sanofi Pasteur
      address:
         name:Sanofi Pasteur, Swiftwater, USA
         type:PostalAddress
      name:Sanofi Pasteur
      address:
         name:Sanofi Pasteur, Swiftwater, USA
         type:PostalAddress
      name:Translate Bio
      address:
         name:Translate Bio, Lexington, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Nicholas A. C. Jackson
      affiliation:
            name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building
            address:
               name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kent E. Kester
      url:http://orcid.org/0000-0002-5056-0802
      affiliation:
            name:Sanofi Pasteur
            address:
               name:Sanofi Pasteur, Swiftwater, USA
               type:PostalAddress
            type:Organization
      name:Danilo Casimiro
      affiliation:
            name:Sanofi Pasteur
            address:
               name:Sanofi Pasteur, Swiftwater, USA
               type:PostalAddress
            type:Organization
      name:Sanjay Gurunathan
      affiliation:
            name:Sanofi Pasteur
            address:
               name:Sanofi Pasteur, Swiftwater, USA
               type:PostalAddress
            type:Organization
      name:Frank DeRosa
      affiliation:
            name:Translate Bio
            address:
               name:Translate Bio, Lexington, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs building, London, UK
      name:Sanofi Pasteur, Swiftwater, USA
      name:Sanofi Pasteur, Swiftwater, USA
      name:Sanofi Pasteur, Swiftwater, USA
      name:Translate Bio, Lexington, USA

Social Networks {πŸ‘}(1)

External Links {πŸ”—}(240)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Prism.js
  • Zoom.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {πŸ“¦}

  • Crossref

5.37s.